| Nov 8 |
Santen, Arctic Vision sign deal for ARVN001 to treat UME
|
| Nov 7 |
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
|
| Nov 6 |
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
|
| Nov 4 |
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors
|
| Oct 31 |
Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024
|
| Oct 22 |
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting
|
| Oct 10 |
Morning Movers: Arcadium Lithium surges after deal to be acquired
|
| Oct 9 |
Clearside stock falls 12% amid Phase 2 data for CLS-AX
|
| Oct 9 |
Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study
|
| Oct 9 |
Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes
|
